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Recent decades have witnessed remarkable progress in cancer immunotherapy 
as an approach to enhancing host immune response against cancer. Particularly, a 
cancer vaccine comprised of antigen, vaccine adjuvant, and delivery system has 
gained widespread attention, which can elicit immune response by activating dendritic 
cells (DCs), the critical antigen-presenting cells (APCs) 1.  
In the past decades, nanoformulations have gained extensive attention as drug 
carriers for improved cancer immunotherapy. Imidazoquinoline-based toll-like 
receptor (TLR) 7 agonist, imiquimod (IMQ), a cytokine inducer, could elicit DC 
activation. TLR7 activation stimulates myeloid differentiation primary-response gene 
88 (MyD88) signaling pathways, elicit DCs to upregulate costimulatory molecules, 
secrete type I interferons and pro-inflammatory cytokines, and stimulate T cell- 
mediated immune response 2.  
The development of a variety of nanoformulations as drug carriers, such as 
polymeric poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) and liposomes, has 
broadened the application of TLR7 agonist in cancer immunotherapy. However, an 
improved understanding of how formulation factors could influence the immune 
response to nanocarriers encapsulating TLR 7 agonist can drive the discovery of more 
efficient platforms to deliver TLR 7 agonist to immune system for enhanced cancer 
immunotherapy. In this thesis, we encapsulated IMQ in PLGA NPs that were either 
naturally anionic or modified with didodecyldimethylammonium bromide (DMAB) 
to generate cationic surface charge. In addition, 18:0 PC 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) and 1,2-dioleoyl-3-trimethylammonium-propane (chloride 
salt) (DOTAP) were employed to formulate IMQ-loaded anionic DSPC liposomes and 
cationic DOTAP liposomes. These formulations were evaluated for in vitro DC 
activation and antigen presentation with a model antigen, ovalbumin (OVA), using 
bone marrow-derived dendritic cells (BMDCs) and DC 2.4 cell line. Cell viability 
assay showed that PLGA NPs and DSPC liposomes showed negligible cytotoxicity 
on BMDCs and DC 2.4 cells at low concentrations, whereas DMAB-PLGA NPs and 
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DOTAP liposomes exhibited obvious cytotoxicity at relatively low concentrations. 
Also, anionic PLGA NPs were superior to other nanoformulations in eliciting 
costimulatory molecule expression by DCs, whereas cationic DOTAP liposomes were 
superior in inducing antigen presentation by DCs compared with other 
nanoformulations.  
Overall, our studies demonstrated that IMQ loaded PLGA NPs showed both 
better biocompatibility and stronger DC activation efficacy compared with other 
formulations. However, further studies are needed to understand the mechanism of 
formulation effects on immune response to nanocarriers encapsulating TLR 7 agonist. 
Definitely, the development of more efficient drug delivery systems encapsulating 
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1.1 Introduction to cancer immunotherapy 
Cancer immunotherapy has shifted the cancer treatment paradigm from directly 
killing tumor cells to the activation of host immune system to induce potent antitumor 
immune response with the potential for fewer off-target effects 3. Agents used in 
cancer immunotherapeutics, activating host immune cells to induce tumor cell death, 
have demonstrated promising results in clinical applications 4, 5. Nevertheless, 
antitumor efficacy of cancer immunotherapy is often hindered by delivery barriers as 
well as immunosuppressive tumor microenvironment 3, 6. Thus, both the enhancement 
of delivery efficacy and modulation of tumor microenvironment are required for 
improving clinical outcome of cancer immunotherapeutics. 
Cancer immunotherapies approved by US Food and Drug Administration (FDA) 
mainly involve chimeric antigen receptor (CAR) T cells, cytokines for lymphocyte 
activation, checkpoint inhibitors, and cancer vaccines 3. The CAR T cell approach is 
a highly personalized anticancer therapy. Briefly, T cells collected from tumor-bearing 
patients are genetically engineered to express CARs specific for antigens displayed 
on cancer cells. Upon re-administration of engineered T cells to the same patient, CAR 
T cells are able to recognize the targeted tumor antigen and kill tumor cells 7, 8.  
Cytokines used in cancer immunotherapy are injected directly to activate 
immune response 3. Lymphocyte promoting cytokines involve three main types, 
interferons, interleukins, and granulocyte–macrophage colony-stimulating factor 
(GM-CSF) 9. Immune checkpoint inhibitors are considered as one of the most 
promising immunotherapies. Two most widely used checkpoint inhibition strategies 
are CTLA4 blockade and PD-1/PD-L1 inhibition, which induce T cell-mediated 
tumor cell death through the removal of co-inhibitory signals preventing anticancer T 
cell function 10.  Cancer vaccine approaches for immunotherapy are described in 
more detail in the next section.  
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1.2. Cancer vaccine principles and hurdles 
Cancer vaccines are recognized as one of the most promising strategies in the 
field of immunotherapy, with their unique capability of targeting immune cells and 
co-delivering antigen and adjuvants to induce antitumor immune response 11. To date, 
remarkable progress has been made in the production of cancer vaccine for clinical 
cancer treatment. The autologous tumor-cell vaccine has been demonstrated to induce 
immune response in melanoma-bearing patients 12. In addition, cancer vaccines 
derived from whole allogeneic cells also have many advantages. Melacine, an 
allogeneic melanoma tumor cell lysate vaccine, showed survival benefits in clinical 
trials 13.  
An effective cancer vaccine consists of three essential components: antigen, 
adjuvant, and delivery system 14. Antigens are molecules, such as peptides, proteins 
or lipids, which are detected by the immune system and elicit an antigen-specific 
immune response. Adjuvants act as stimulants of immune system and are able to 
influence the profile of induced immune response, while the delivery system is a 
platform that enables optimal co-delivery of antigen and adjuvant for the effective 
activation of both innate and adaptive immune systems 14. It has been demonstrated 
that the efficacy of a cancer vaccine can be significantly improved by developing 
delivery tools capable of protecting and delivering antigens and adjuvants 
simultaneously 15.  
One of the main obstacles of cancer vaccine development is the selection of 
appropriate antigens 14. In order for potent antitumor immune response, sufficient 
tumor associated antigens (TAAs) are required for the activation of dendritic cells 
(DCs), leading to T cell proliferation and differentiation into effector cells 16. TAAs 
can be of several types. Two main categories are shared tumor antigens and unique 
tumor antigens. Shared tumor antigens are overexpressed by multiple types of tumor, 
whose expression on healthy tissues is either absent or quantitatively different, such 
as melanoma-assiciated antigen (MAGE) and Cancer/Testis Antigen 1B (CTAG1B) 
17, 18. The second category comprises antigens, which are expressed uniquely by 
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individual tumors and correspond to new epitopes 19.  However, most TAAs have 
several drawbacks when tested in vivo, including risk of low immunogenicity, 
problems of antigen processing and presentation, and slow and weak antigen-specific 
T cell response 14. Apart from problems relevant to tumor antigens, additional hurdles 
of the application of cancer vaccine have to be overcome. Barriers contribute to the 
ineffectiveness of cancer vaccines also include T cell exhaustion by immune 
checkpoint molecules, such as PD-1/PD-L1 and CTLA 4, expression of 
immunosuppressive molecules, such as interleukin-10, and MHC class I and T cell 
relevant tumor antigen downregulation by tumor cells 20-23. Finally, selecting the 
optimal dose of cancer vaccines as well as the validation of evaluation methods of 
their effectiveness are both challenging 14. Undoubtedly, well-designed studies are 
required for further improving the efficacy of cancer vaccines and broadening their 
therapeutic benefits in clinical application.  
 
 
1.3. Toll-like receptor (TLR) signaling for DC activation 
TLRs, sensors for pathogens, consist of an extracellular region, containing 
leucine-rich repeat motifs, and a cytoplasmic tail, which has a Toll/interleukin-1(IL-
1) receptor (TIR) domain. One of the mechanisms by which the host immune system 
detects the invasion of pathogenic microbes is through TLRs 24. Recognition of 
pathogen-associated molecular patterns (PAMPs) via TLRs activates DCs, causing 
initiation of adaptive immunity. TLR signaling in DCs leads to an increase in 
expression of MHC peptide ligands, upregulation of costimulatory molecules and 
secretion of immunomodulatory cytokines, critical for T cell expansion and 
differentiation into effector T cells 25. There are twelve expressed TLR genes in mice 
and ten in humans. Each TLR is dedicated to the recognition of a distinct set of 
molecular patterns 26. In humans, TLRs 1, 2, and 6, cell surface receptors, recognize 
lipids. TLRs 4 and 5 are also located on the cellular membrane of DCs, which 
recognize lipopolysaccharide (LPS) and flagellin, respectively. TLRs 3, 7, 8, and 9 are 
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endosomal nucleotide sensors. TLR 3 is activated by double-stranded RNA, while 
TLR 7 and TLR 8 are stimulated by single-stranded RNA, moreover, TLR 9 
recognizes unmethylated CpG dinucleotides 26. 
    After ligand binding, TLRs signaling elicits a range of intracellular responses. 
TLRs 1, 2, 4, 5, 6, 7, 8, and 9 stimulate MyD88, while TLR 3 activates only TIR 
domain-containing adaptor protein inducing IFNβ (TRIF) signaling pathway 26. The 
TRIF signaling stimulates interferon regulatory factor (IRF) to induce type I interferon 
gene expression, furthermore, myeloid differentiation primary-response gene 88 
(MyD88) signaling activates mitogen-activated protein kinases (MAPKs), the 
transcription factor nuclear factor-kappa B (NF-κB), and members of IRF family, 
leading to the secretion of type I interferon and diverse pro-inflammatory cytokines, 
such as interleukin-12 and tumor necrosis factor alpha (TNF-α) 26.  
 
 
1.4. TLR 7/8 agonists as immunostimulatory adjuvants of cancer vaccine 
TLR agonists are one of the most commonly used vaccine adjuvants, which are 
co-administered with TAA for enhanced vaccine-based cancer immunotherapy. 
Specifically, synthetic small molecule imidazoquinolines, such as imiquimod (IMQ), 
resiquimod, and their derivatives, are effective TLR 7 or TLR 8 specific or TLR 7/8 
bispecific agonists. They have demonstrated great potential as vaccine adjuvants, 
since they are able to improve the immunogenicity of TAA and enhance antigen-
specific immune response 27.  
IMQ, TLR 7 specific agonist, was approved by FDA for the treatment of basal 
cell carcinoma in 1997 28. Both IMQ and resiquimod are cytokine inducers, capable 
of activating plasmacytoid DCs, the primary interferon-producing cells, to stimulate 
interferon-α secretion 29. They also induce the production of interleukin-12 and TNF-
α, and enhance costimulatory marker expression 29, 30. These secreted cytokines are 
able to further contribute to T cell proliferation and differentiation into CD8+ cytotoxic 
T lymphocyte (CTL) and induce T cell-mediated immunity 31. The chemical structure 
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of IMQ and resiquimod are shown in Figure 1.  
(A)                             (B) 
                
Figure 1. Chemical structure of IMQ (A) and resiquimod (B) 
 
 
1.5. Biodegradable nanoparticles (NPs) as vaccine delivery system 
To date, numerous studies have shown the success of biodegradable NPs as 
vaccine delivery vehicles for cancer immunotherapy 34, 35. In order to fabricate 
effective vaccine delivery systems, extensive research has been conducted to evaluate 
the antigen uptake, processing into peptides and presentation via MHC class I by DCs, 
and DC migration to lymph nodes and maturation. These are the key steps in 
triggering robust antigen-specific immune response 36.  
Uptake of biodegradable NPs by DCs depends on several physiochemical 
properties, including size, surface charge, shape, as well as hydrophobicity and 
hydrophilicity 14, 36. Among these factors, size and surface charge of NPs play a crucial 
role in the internalization by DCs. It is reported that the optimal particle diameter for 
efficient DC uptake was ≤ 0.5 μm 37. NPs within this size range might further trigger 
both humoral and cellular immune response. However, uptake of larger NPs by DCs 
could be improved by rendering the particle surface positive, which may arise from 
the greater affinity of positively charged molecules to the negatively charged cell 
membrane 14, 37. Nevertheless, studies also suggested that the influence of particle 
surface charge on interaction with DCs is different for particles with diameter below 
0.5 μm, and small-sized, anionic particles may have advantages over cationic particles, 
which may result in non-specific interaction with other cell types 37. In addition, 
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intracellular trafficking studies indicated that some of cationic NPs could escape from 
lysosomes after being internalized and exhibit perinuclear localization, while the 
anionic and neutral NPs prefer to colocalize with lysosomes 38. However, the 
interpretation of zeta potential effects on NP internalization by DCs can be 
complicated, and more thorough research is needed. Apart from general 
physiochemical characteristics, specific interactions arising from molecular 
functional groups of synthesized biodegradable NPs can be expected to exert an 
influence on NP interaction with DCs.  
 
 
1.5.1 Poly(lactide-co-glycolide) (PLGA) NPs as delivery vehicles of TLR agonists 
PLGA, a biocompatible and biodegradable FDA-approved copolymer, which 
could be hydrolyzed into lactic and glycolic acid monomers, has been extensively 
used in fabricating nanocarriers for drug delivery 39, 40. PLGA-based NPs enable the 
encapsulation and delivery of a wide range of agents, including proteins, peptides, 
plasmid DNA, and hydrophilic or lipophilic drugs 41-44. Moreover, the physiochemical 
properties of different PLGA-based NPs (size, morphology, zeta potential, drug 
release kinetics, degradation time), can be tuned by controlling molecular weight and 
copolymer ratio of PLGA, as well as parameters specific to the synthetic method 45, 
46.  
Poly (vinyl alcohol) (PVA) is a widely-used surfactant in formulating PLGA 
NPs with emulsion solvent evaporation method, which is able to generate relatively 
small particles with uniform size distribution 47. The amount of residual PVA 
remaining associated with PLGA NPs has been shown to be a significant formulation 
parameter, which could affect the cellular uptake of NPs 48. Furthermore, the 
introduction of didodecyldimethylammonium bromide (DMAB), a cationic surfactant, 
to modify PLGA-based NPs renders the particle surface charge positive and increases 
the stability of NPs 49, 50. The properties and function of PLGA-based NPs could be 
further modulated by ligand attachment to the surface. For instance, ‘PEGlyation’, 
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attaching poly(ethylene glycol) (PEG) chains to the surface of PLGA NPs, is able to 
prolong the circulation half-life of NPs in vivo 51. Furthermore, multiple ligands have 
been employed in the functionalization of PLGA-based NPs, including peptides, 
antibodies, proteins, glycolipids, and glycoproteins, to facilitate targeted drug delivery 
46.  
In addition to these promising results and applications, several studies have 
shown that PLGA-based NPs encapsulating TLR 7/8 agonists could achieve a 
sustained drug release profile and trigger DC activation and T cell response when co-
administered with antigens 2, 34. Furthermore, PLGA NPs containing poly(I:C) (TLR 
3 agonist) or CpG oligodeoxynucleotide (ODN) (TLR 9 agonist) together with OVA 
were efficient at inducing antigen presentation by DCs and eliciting robust CTL 
responses 52. Another study established that co-delivery of 7-acyl lipid A (TLR 4 
agonist) and cancer-associated antigen by PLGA NPs could enhance DC maturation, 
trigger potent CD8+ T cell response against cancer, and promote the secretion of pro-
inflammatory cytokines 53. These studies demonstrate the potential of PLGA-based 
NPs as competent vaccine delivery platforms.  
 
 
1.5.2 Liposomes as delivery platforms of TLR agonists 
It was discovered in the 1960s that hydration of dry lipid film in aqueous media 
could generate enclosed spherical vesicles or liposomes with lipid bilayers 54. 
Generally, liposomes are composed of natural and/or synthetic lipids (phospho- and 
sphingo-lipids), which may also contain other bilayer components, such as cholesterol 
and hydrophilic polymer conjugated lipids 55. What makes liposomes attractive 
delivery systems are their bilayered nature, which allows hydrophilic components to 
be either encapsulated into the inner aqueous core or adsorbed onto the liposomal 
surface, whereas the lipophilic part of the liposomes enables hydrophobic components 
to be incorporated within the membrane bilayers 56. In addition, liposomal 
formulations can be optimized by altering their physicochemical characteristics, 
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including size, surface charge, surface hydration, and the fluidity of bilayer membrane, 
which exert a significant influence on the performance of liposomes in vitro and in 
vivo 55.  
With more extensive studies and remarkable advancement in biomedical science, 
liposomes have been recognized as versatile biodegradable and biocompatible drug 
carriers to enhance the delivery efficiency of therapeutic agents 57. Liu et al. developed 
a liposomal drug carrier through the attachment of substrate of endoprotease legumain, 
alanine–alanine–asparagine (AAN), to cell-penetrating peptides (TAT, trans-
activating factor), to enhance the delivery efficiency of doxorubicin for cancer 
treatment and limit its toxic effects 58. Moreover, Zhou et al. incorporated a 
mitochondrial targeting molecule onto the surface of paclitaxel liposomes, which 
showed potent anticancer efficacy for treating the drug-resistant lung cancer 59. Also, 
Maruyama et al. designed the pendant type immunoliposome (34A-PEG-ILP), which 
was a long-circulating PEG-immunoliposome attached antibodies at the distal end of 
PEG chain 60. Their study revealed that 34A-PEG-ILP exhibited much greater 
targetability to sites of action, solid tumor tissue and lung endothelial cells, compared 
with ordinary immunoliposomes. 
In addition, recent studies have shown the potential of liposomes as vaccine 
delivery systems. Over the last few decades, the combination of liposomes with potent 
immunostimulatory adjuvants has arisen as a promising vaccine delivery platform for 
immunotherapy 61-63. Poly(I:C) was effectively encapsulated into cationic liposomes 
with a high loading efficiency (> 96%), and poly(I:C)-loaded liposomes were capable 
of evoking a strong IgG1/IgG2a response 64. Additionally, the co-encapsulation of 
OVA and CpG or PAM3CSK4 (TLR 2 ligand) in cationic liposomes was able to evoke 
DC activation, induce the production of IgG 2a and IgG1antibodies, trigger a robust 
cellular immune response, and promote the secretion of interferon-γ 65. It was also 
reported that a nanoliposome delivery system that co-localized IMQ as well as GLA 
(TLR 4 agonist) could enhance Th1 adaptive immune responses and facilitate the 
production of interferon-γ 66. Furthermore, another study demonstrated that liposomes 
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containing 3M-019, a new TLR 7 ligand, could induce IgG2a and IgG2b antibody 
response and trigger strong cellular immune response, leading to more powerful 
immunity than either TLR 7 ligand or liposomes alone 67.  
Even though numerous studies have examined the influence of different antigens 
and adjuvants on inducing immune cell activation and immune response, further 
research is needed to dissect the influence of delivery systems on the efficacy of 
cancer vaccine. Furthermore, although both PLGA NPs and liposomes have been 
widely used as drug delivery platforms, the comparison of PLGA NPs with liposomes 
as delivery vehicles for cancer vaccine adjuvants may contribute to the discovery of 
more efficient drug carriers as vaccine delivery systems for enhanced cancer 
immunotherapy. In the present study, we fabricated cationic and anionic PLGA NPs 
as well as liposomes as four types of drug carriers, encapsulating the same 
immunostimulatory adjuvant, IMQ. Also, these nanoformulations were co-
administered with the same model antigen, ovalbumin (OVA), to carry out in vitro 
studies in order to evaluate their influence on DC activation and antigen presentation.  
 
 
1.6. Specific Aims 
Specific aims of this study are as follows: 
Specific aim 1. Development of cationic and anionic PLGA NPs as well as liposomes 
as drug carriers for TLR 7 agonist delivery. 
Specific aim 2. In vitro evaluation of four types of nanocarriers on DC activation and 









2. Materials and Methods  
 
2.1. Materials 
PLGA (50:50 lactide-glycolide ratio; 0.55-0.75 dl/g inherent viscosity) was 
purchased from Lactel (Birmingham, AL). DMAB, IMQ, PVA, ammonium acetate 
and OVA from chicken egg white were purchased from Sigma-Aldrich (St Louis, MO). 
Chloroform and acetonitrile were purchased from Fisher Scientific (Rockford, IL). 
Fluorophore-labeled monoclonal antibodies were purchased from Biolegend (San 
Diego, CA) (CD80, CD86, CD11c, CD40, (I-A/I-E (MHC II)). 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (ammonium 
salt) (DSPE-PEG), cholesterol, 18:0 PC 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) and 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP) 
were purchased from Avanti Polar Lipids (Alabaster, AL). All cell culture media and 
buffers (including phosphate buffered saline) were purchased from Life Technologies 
(Carlsbad, CA) or Corning (Tewksbury MA).  
 
 
Animals and cell lines 
C57BL/6 mice (6-8 weeks, female) were purchased from Charles River 
(Wilmington, MA). Mice were housed under specific pathogen free (SPF) facilities in 
Research Animal Resources at the University of Minnesota. All animal experiments 
were performed according to the protocols approved by Institutional Animal Care and 
Use Committee (IACUC) of the University of Minnesota. DC 2.4 cell line was 
provided by Professor Chun Wang, University of Minnesota.  
 
 
2.2. Fabrication of IMQ loaded PLGA NPs 
IMQ loaded PLGA NPs were prepared using the water-in-oil-in-water (w/o/w) 
double-emulsion solvent evaporation technique 2. The aqueous phase of primary w/o 
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emulsion was prepared by dissolving 2.5 mg of sodium bicarbonate in 500 μl of 1% 
w/v PVA in endotoxin-free distilled water (D.I. water). This aqueous phase was then 
added to the oil phase, which comprised 30 mg PLGA and 1.5 mg IMQ dissolved in 
2 ml chloroform. The mixture was sonicated using a probe sonicator (Sonicator XL, 
Misonix, Melville, NY) for 1 min to generate w/o emulsion. The primary emulsion 
was then transferred to 8 ml of 2% w/v PVA solution and sonicated for 5 min to 
generate the secondary w/o/w emulsion. The final emulsion was stirred at room 
temperature for ~18 h, followed by 1 h of vacuum in a desiccator to evaporate 
chloroform. NPs were separated and washed by ultracentrifugation (Optima XPN-80 
Ultracentrifuge, Beckman Coulter Inc., Fullerton, CA) (35,000 RPM, 35 min) and 
then resuspended in D.I. water. This procedure was repeated twice to remove 
unencapsulated drug and residual PVA. After final wash, NPs were dispersed in D.I. 
water containing 20 mg sucrose (cryoprotectant). PLGA NPs were then lyophilized 
(Labconco FreeZone 4.5, Kansas City, MO) and stored at -20 °C until further use. 
 
 
2.3. Fabrication of IMQ loaded DMAB-PLGA NPs 
DMAB modified IMQ loaded PLGA NPs were formulated using the 
aforementioned double-emulsion solvent evaporation technique with modifications. 
The aqueous phase of primary w/o emulsion was prepared by dissolving 2.5 mg of 
sodium bicarbonate in 500 μl of 1% w/v PVA in D.I. water. This aqueous phase was 
then added to the oil phase, which comprised 30 mg PLGA and 1.5 mg IMQ dissolved 
in 2 ml chloroform. The mixture was sonicated using probe sonicator (Sonicator XL, 
Misonix, Melville, NY) for 1 min to generate w/o emulsion. The primary emulsion 
was then transferred to 8 ml of 2% w/v PVA solution and sonicated for 5 min to 
generate the secondary w/o/w emulsion. The final emulsion was stirred in room 
temperature for ~18 h, followed by 1 h of vacuum in a desiccator to evaporate 
chloroform. NPs were separated and washed by ultracentrifugation (Optima XPN-80 
Ultracentrifuge, Beckman Coulter Inc., Fullerton, CA) (35,000 RPM, 35 min) and 
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then resuspended in D.I. water. This procedure was repeated once to remove 
unencapsulated drug and residual PVA. Modification with DMAB was performed by 
resuspending NP pellets after the third centrifugation step in 1% w/v aqueous DMAB 
solution, followed by stirring overnight at room temperature. To remove unbound 
DMAB, NPs were then washed twice by ultracentrifugation and dispersed in D.I. 
water containing 20 mg sucrose (cryoprotectant). DMAB modified PLGA NPs were 
then lyophilized and stored at -20°C until further use.  
 
 
2.4. Fabrication of IMQ loaded DSPC-liposomes 
DSPC, cholesterol, and DSPE-PEG were dissolved in chloroform at a mole ratio 
of (65:31:4.5). The solvent was evaporated under vacuum overnight to generate lipid 
films. IMQ acetate buffer solution was prepared by dissolving 3 mg IMQ in 2.5 ml 
acetate buffer (pH 3.3). The dried lipid film was hydrated with IMQ acetate buffer 
solution at 60 °C for 1 h with intermittent vortex. The lipid suspension then underwent 
water bath sonication to generate liposomes dispersion (until the suspension changes 
from milky to nearly clear in appearance). Liposomes were then separated from free 
drug via size exclusion chromatography with a disposable PD-10 column (GE 
Healthcare, Pataskala, OH), and the buffer was exchanged for PBS (pH 7.4). The 
liposomes obtained were stored at 4 °C prior to use. 
 
 
2.5. Fabrication of IMQ loaded DOTAP liposomes 
DOTAP and cholesterol were dissolved in chloroform at a molar ratio of 1:1. The 
solvent was evaporated under vacuum overnight to generate lipid films. IMQ acetate 
buffer solution was prepared by dissolving 3 mg IMQ in 2.5 ml acetate buffer (pH 
3.3). The dried lipid film was hydrated with IMQ acetate buffer solution at 60 °C for 
1 h with intermittent vortex. The lipid suspension then underwent water bath 
sonication to generate liposomes dispersion (until the suspension changes from milky 
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to nearly clear in appearance). Liposomes were then separated from free drug via size 
exclusion chromatography with a disposable PD-10 column (GE Healthcare, 
Pataskala, OH), and the buffer was exchanged for PBS (pH 7.4). The liposomes 
obtained were stored at 4 °C prior to use. 
 
 
2.6. Physiochemical characterization of NPs and liposomes 
Size and zeta potential of NPs and liposomes were determined by dynamic light 
scattering (DLS) (Delsa™ Nano C, Beckman Coulter Inc.). For PLGA NPs and 
DMAB modified PLGA NPs, ~1 mg of NPs was dispersed in D.I. water and sonicated 
before measurements. For DSPC liposomes and DOTAP liposomes, 100 μl of 
liposomes dispersion was diluted in D.I. water before measurements. The amount of 
IMQ encapsulated into the NPs or liposomes was quantified using Ultraviolet (UV) 
analysis. Lyophilized NPs or liposomes were first dispersed in methanol at a 
concentration of 1 mg/ml and incubated overnight in room temperature. The 
dispersion was centrifuged at 13,000 RPM for 15 min and 100 μl of the supernatant 
was collected. The supernatant was then evaporated and redissolved in acetate buffer 
(pH 3.3) for UV analysis at a detection wavelength of 319 nm.  
 
 
2.7. Culture of BMDCs 
BMDCs were prepared using established protocols with modifications. Briefly, 
femurs and tibia were harvested from C57BL/6 mice, disinfected with 70% ethanol, 
and rinsed with PBS (pH 7.4). Bone marrow precursor cells were collected by flushing 
with PBS using a 27-gauge needle (Medtronic, Minneapolis, MN). The flushed bone 
marrow was filtered with a 70-μm nylon mesh, and erythrocytes were removed using 
lysis buffer (Pharm Lyse, BD Bioscience, San Jose, CA). After centrifugation, bone 
marrow precursor cells were seeded into petri dish and cultured with complete RPMI 
1640 media supplemented with 20 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ) and 
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50 μM 2-mercaptoethanol (Sigma) at 37 °C with 5% CO2 . BMDCS culture media 
was refreshed once on day 3, and it took 6 days to generate immature BMDCs.  
 
 
2.8. Culture of DC 2.4 cells 
DC 2.4 cells are immortalized murine DCs created by transducing bone marrow 
isolates of C57BL/6 mice with retrovirus vectors expressing murine GM-CSF and the 
myc and raf oncogenes. DC 2.4 cells between passages 7-10 were used for the study. 
Cells were cultured using established protocols with modifications 68. Briefly, DC 2.4 
cells were cultured in complete RPMI 1640 media supplemented with 10mM HEPES 
Buffer Solution and 0.0054×2-mercaptoethanol (Sigma) at 37°C in a humidified 
atmosphere containing 5% CO2.  
 
 
2.9. Cell Viability Assay 
BMDCs or DC 2.4 cells (10,000 cells/well) were seeded in a 96-well cell culture 
plate. Following cell attachment, BMDCs or DC 2.4 cells were treated with free IMQ 
(0.625, 1.25, 2.5, 5, 10, 20μM), IMQ loaded PLGA NPs, DMAB modified PLGA NPs, 
DSPC liposomes and DOTAP liposomes and blank NPs or liposomes for 24 h. The 
amount of loaded NPs or liposomes added was based on the drug loading to produce 
the same concentration as free IMQ. The concentration of blank NPs or liposomes 
was the same with the respective loaded ones. Treatments were incubated with 
BMDCs or DC 2.4 cells for 24h and cell viability was analyzed using MTS assay.  
 
 
2.10. In vitro BMDCS and DC 2.4 cells activation  
BMDCs or DC 2.4 cells (0.5×106/well) were seeded in a 24-well cell culture 
plate. Following cell attachment, BMDCs or DC 2.4 cells were treated with OVA 
(20μg) alone or OVA combined with free IMQ(100 ng/ml), IMQ loaded PLGA NPs, 
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DMAB modified PLGA NPs, DSPC liposomes and DOTAP liposomes and blank NPs 
or liposomes for 24 h. The amount of loaded NPs or liposomes added was based on 
the drug loading to produce the same concentration as free IMQ. The amount of blank 
NPs or liposomes was the same with the respective loaded ones. After 24 h, BMDCs 
or DC 2.4 cells were collected and analyzed for costimulatory molecules (CD40, 
CD86, and CD80) by flow cytometry.  
 
 
2.11. In vitro antigen presentation by BMDCS or DC 2.4 cells 
To assess in vitro antigen presentation, BMDCs or DC 2.4 cells (0.5×106/well) 
were seeded in a 24-well cell culture plate. Following cell attachment, BMDCs were 
treated with OVA (20 μg) alone or OVA combined with free IMQ (100 ng/ml), IMQ 
loaded PLGA NPs, DMAB modified PLGA NPs, DSPC liposomes and DOTAP 
liposomes and blanks NPs or liposomes for 24 h. The amount of loaded NPs or 
liposomes added was according to the drug loading to maintain the same 
concentration as free IMQ. The amount of blank NPs or liposomes was the same with 
the respective loaded ones. After 24 h, BMDCs or DC 2.4 cells were harvested and 
stained with anti-CD11c antibody and anti-OVA257-264 (SIINFEKL) peptide bound to 





3.1. Physiochemical Characterization of PLGA NPs and Liposomes 
The hydrodynamic size of four types of nanoformulations was measured by DLS. 
PLGA NPs and DMAB- PLGA NPs had a similar average diameter (~250 nm), while 
the average diameter of DSPC liposomes and DOTAP liposomes was ~100 nm. PLGA 
NPs and DSPC liposomes were both negatively charged, with an average zeta 
potential of~ -25 mV, whereas DMAB-PLGA NPs and DOTAP liposomes were both 
16 
 
positively charged. The average zeta potential of DMAB-PLGA NPs was 23 ± 5.8 mV, 
however, DOTAP liposomes had a higher zeta potential of ~ 50 mV. The loading 
amount of IMQ in PLGA NPs and DMAB-PLGA NPs were similar at ~20 μg/mg, but 
the drug loading of both DSPC liposomes and DOTAP liposomes was smaller at ~10 
μg/mg. (Table 1) 
 
Table 1: Physicochemical characterization of NPs and liposomes 




Size (nm) 249 ± 36.5 274 ± 18.1 98 ± 11.4 100 ± 7.7 
Zeta potential(mV) -24 ± 11.2 23 ± 5.8 -26 ± 2.5 50 ± 25.4 
PDI 0.2 ± 0.07 0.2 ± 0.08 0.2 ± 0.01 0.2 ± 0.07 
Loading amount of IMQ 
(μg/mg NP or liposomes) 
20.6 ± 5.0 23.8 ± 4.2 9.5 ± 1.2 8.75 ± 2.54 
 
 
3.2. Cell viability assays 
Cytotoxicity was evaluated in BMDCs (primary cells) and DC 2.4 (immortalized 
cells) by MTS assay. Nine treatments with concentrations (0.625, 1.25, 2.5, 5, 10, 
20μM) were used in this study, including free IMQ, loaded PLGA NPs, loaded PLGA-
DMAB NPs, loaded DSPC liposomes, loaded DOTAP liposomes, blank PLGA NPs, 
blank PLGA-DMAB NPs, blank DSPC liposomes, and blank DOTAP liposomes. 
Results indicated that free IMQ promoted the growth of BMDCs at low concentrations, 
but showed cytotoxicity at concentrations higher than 10 μM. Furthermore, both 
loaded PLGA NPs and DSPC liposomes, as well as their blank formulations have 
negligible cytotoxicity against primary cells. Nevertheless, both loaded DMAB-
PLGA NPs and DOTAP liposomes, as well as their blank formulations showed 





Figure 2. Cell viability of BMDCs  
(A) Cell viability of BMDCs on treatments with free IMQ and IMQ loaded NPs and 
liposomes. Results are reported as mean ± SD, n=5. (B) Cell viability of BMDCs on 
treatments with free IMQ and blank NPs and liposomes. Results are reported as mean 
± SD, n=5. 
 
With regards to DC 2.4 cells, free IMQ also induced cell growth at concentrations 
lower than 5 μM, but showed cytotoxicity at concentrations higher than 10 μM. 
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Similar to primary cells, both loaded PLGA NPs and DSPC liposomes as well as their 
blank formulations show negligible cell-killing effects against immortalized cells. 
However, both loaded and blank DMAB-PLGA NPs showed cytotoxicity to DC 2.4 
at concentrations greater than 2.5 μM. Also, both loaded DOTAP liposomes and its 
blank counterparts showed cytotoxicity at concentrations greater than 5 μM. 
 
 
Figure 3. Cell viability of DC 2.4  
(A) Cell viability of DC 2.4 on treatments with free IMQ and IMQ loaded NPs and 
liposomes. Results are reported as mean ± SD, n=5. (B) Cell viability of DC 2.4 on 
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treatments with free IMQ and blank NPs and liposomes. Results are reported as mean 
± SD, n=5. 
 
 
3.3. In vitro BMDCs activation 
Here, we evaluated the expression of costimulatory molecules (CD40, CD80 and 
CD 86) to examine the extent of BMDC activation. As a model antigen, OVA was 
treated alone or co-administered with nine treatments, free IMQ, loaded PLGA NPs, 
loaded PLGA-DMAB NPs, loaded DSPC liposomes, loaded DOTAP liposomes, 
blank PLGA NPs, blank PLGA-DMAB NPs, blank DSPC liposomes, and blank 
DOTAP liposomes. As is indicated, OVA alone had a smaller effect on the expression 
of CD40 compared with OVA+free IMQ, OVA+loaded PLGA NPs, OVA+loaded 
DMAB-PLGA NPs and OVA+loaded DOTAP liposomes. CD 40 expression increased 
from 25% for OVA alone treatment to 50% for OVA+DOTAP liposomes treatment, 
70% for OVA+DMAB-PLGA NPs, 76% for OVA+free IMQ treatment, and 92% for 
OVA+PLGA NPs treatment. However, CD 40 expression in all blank formulations 
and loaded DSPC liposomes with OVA was similar to OVA alone group.  
In addition, CD80 expression by BMDCs was likely in treatments with OVA 
alone, OVA+free IMQ, OVA+blank PLGA NPs, OVA+blank/loaded DMAB-PLGA 
NPs, OVA+blank/loaded DSPC liposomes, and OVA+blank/loaded DOTAP 
liposomes. However, OVA+loaded PLGA NPs treatment increased the frequency of 
BMDC expressing CD80 to 32%, whereas OVA alone treatment only resulted in 12% 
of CD80 expression. Furthermore, OVA+free IMQ treatment induced slightly higher 
CD86 expression of BMDCs in comparison with OVA alone treatment as well as all 
blank formulations together with OVA (5%~10%). OVA+loaded PLGA NPs treatment 
led to the highest BMDC expression of CD86 (26%), whereas OVA+DMAB-PLGA 
NPs treatment caused the lowest CD86 expression, 7%. However, the frequency of 
CD86 expression in treatments of OVA alone, OVA+free IMQ, OVA+loaded DSPC 
liposomes and OVA+loaded DOTAP liposomes were all within the range from 15% 
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Figure 4. Expression of CD 40 on BMDCs  
(A) Flow cytometry analysis of CD40 expression on BMDCs after 24 h incubation 
with OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
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reported as mean ± SD, n=3, ***p<0.001, One-way ANOVA. (B) CD40 expression 
on BMDCs after 24 h incubation with OVA alone, OVA combined with free IMQ, 




Figure 5. Expression of CD 80 on BMDCs  
(A) Flow cytometry analysis of CD80 expression on BMDCs after 24 h incubation 
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with OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
reported as mean ± SD, n=3, ***p<0.001, One-way ANOVA. (B) CD80 expression 
on BMDCs after 24 h incubation with OVA alone, OVA combined with free IMQ, 




Figure 6. Expression of CD 86 on BMDCs  
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(A) Flow cytometry analysis of CD86 expression on BMDCs after 24 h incubation 
with OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
reported as mean ± SD, n=3, *p<0.05, ***p<0.001, One-way ANOVA. (B) CD86 
expression on BMDCs after 24 h incubation with OVA alone, OVA combined with 
free IMQ, blank NPs or liposomes. Results are reported as mean ± SD, n=3. 
 
 
3.4. In vitro DC 2.4 activation 
Apart from primary DCs, we also evaluated the influence of four types of nanocarriers 
together with their blank formulations on the activation of immortalized DCs. 
Treatments were the same as those treated BMDCs. As is shown, OVA+free IMQ 
treatment achieved the highest DC 2.4 expression of CD40 compared with all the other 
treatments. However, treatment of both OVA+loaded DMAB-PLGA NPs and its blank 
counterpart resulted in negligible CD40 expression by DC 2.4 cells. OVA alone 
treatment led to similar CD40 expression frequency (40%) in comparison with 
treatments of OVA+blank PLGA NPs, OVA+blank DSPC liposomes, and OVA+blank 
DOTAP liposomes, whereas OVA alone treatment caused slightly higher expression 
of CD40 compared with OVA+loaded PLGA NPs (23%), OVA+loaded DSPC 
liposomes (28%), and OVA+loaded DOTAP liposomes (30%). Additionally, 
OVA+loaded PLGA NPs treatment achieved the greatest expression frequency of 
CD80 (46%) among all the groups, while treatments of both OVA+loaded DMAB-
PLGA NPs and its blank formulations caused no CD80 expression.  
The frequency of DC 2.4 expressing CD80 were similar in treatments of 
OVA+free IMQ, OVA+loaded DOTAP liposomes and its blank counterparts, 
OVA+blank DSPC liposomes, which was greater than that of OVA+loaded DSPC 
liposomes (11%). Moreover, OVA+free IMQ obtained the highest expression level of 
CD86 among all treatments. OVA alone treatment achieved similar expression 
frequency of CD86 (5.8%) to that of treatments of all blank formulations co-
administered with OVA. Nevertheless, CD86 expression by DC 2.4 cells with OVA 
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alone treatment was higher than that of treatments of all loaded formulations co-
administered with OVA. 
  
 
Figure 7. Expression of CD 40 on DC 2.4  
(A) Flow cytometry analysis of CD40 expression on DC 2.4 after 24 h incubation with 
OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
reported as mean ± SD, n=3. (B) CD40 expression on DC 2.4 after 24 h incubation 
with OVA alone, OVA combined with free IMQ, blank NPs or liposomes. Results are 
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Figure 8. Expression of CD 80 on DC 2.4  
(A) Flow cytometry analysis of CD80 expression on DC 2.4 after 24 h incubation with 
OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
reported as mean ± SD, n=3. (B) CD80 expression on DC 2.4 after 24 h incubation 
with OVA alone, OVA combined with free IMQ, blank NPs or liposomes. Results are 






Figure 9. Expression of CD 86 on DC 2.4  
(A) Flow cytometry analysis of CD86 expression on DC 2.4 after 24 h incubation with 
OVA alone, OVA combined with free IMQ, loaded NPs or liposomes. Results are 
reported as mean ± SD, n=3. (B) CD86 expression on DC 2.4 after 24 h incubation 
with OVA alone, OVA combined with free IMQ, blank NPs or liposomes. Results are 





3.5. In vitro antigen presentation by BMDCs 
Apart from the expression of costimulatory molecules (CD40, CD80, CD86), we 
also examined another key feature of effective DC activation, antigen presentation via 
MHC I, which was measured through evaluating the expression of OVA257-
264(SIINFEKL) peptide:MHC I complex on BMDCs. As is indicated, OVA+free IMQ 
treatment obtained the greatest OVA257-264(SIINFEKL) peptide:MHC I complex 
expression among all the treatments. However, both DMAB-PLGA NPs and its blank 
counterpart co-treated with OVA achieved negligible antigen presentation via MHC I. 
Additionally, the expression frequency of OVA257-264(SIINFEKL) peptide:MHC I 
complex among treatments of OVA alone, both loaded PLGA NPs and its blank 
counterparts together with OVA, both loaded DSPC liposomes its blank counterparts 
together with OVA, and OVA+blank DOTAP liposomes, which was slightly lower 






Figure 10. SIINFEKL: MHC I Expression of BMDCs  
(A) Flow cytometry analysis of BMDCs expressing OVA257-264 (SIINFEKL) peptide 
bound to H-2Kb, after 24 h incubation with OVA alone, OVA combined with free IMQ, 
loaded NPs or liposomes. Results are reported as mean ± SD, n=3. (B) BMDCs 
expressing OVA257-264 (SIINFEKL) peptide bound to H-2K
b, after 24 h incubation 
with OVA alone, OVA combined with free IMQ, blank NPs or liposomes. Results are 
reported as mean ± SD, n=3. 
 
 
3.6. In vitro antigen presentation by DC 2.4 
The extent of antigen expression via MHC I was also investigated in DC 2.4 cells. 
Similar to BMDCs, OVA+free IMQ treatment achieved the hightest OVA257-
264(SIINFEKL) peptide:MHC I complex expression among all the treatments. Also, 
both DMAB-PLGA NPs and its blank counterpart co-treated with OVA achieved no 
antigen presentation via MHC I. Furthermore, among all loaded formulations, 
OVA+DOTAP liposomes obtained the greatest expression frequency of OVA257-
264(SIINFEKL) peptide:MHC I complex (12%). Similarly, the expression level of 






Figure 11. SIINFEKL: MHC I Expression of DC 2.4  
(A) Flow cytometry analysis of DC 2.4 expressing OVA257-264 (SIINFEKL) peptide 
bound to H-2Kb, after 24 h incubation with OVA alone, OVA combined with free IMQ, 
loaded NPs or liposomes. Results are reported as mean ± SD, n=3, *p<0.05, **p<0.01, 
One-way ANOVA. (B) DC 2.4 expressing OVA257-264 (SIINFEKL) peptide bound to 
H-2Kb, after 24 h incubation with OVA alone, OVA combined with free IMQ, blank 




Immunotherapy for cancer treatment aims to activate the host immune system to 
induce potent anticancer immunity through the stimulation of T cells to recognize and 
eliminate cancer cells in an antigen-specific manner 2, 3. Furthermore, TLR signaling 
in DCs could result in an increase in the expression of MHC peptide ligands, 
upregulation of costimulatory molecules and secretion of immunomodulatory 
cytokines, critical for T cell expansion and differentiation into CTL 25. Current 
research has shown the progress in cancer immunotherapy with the development and 
application of cancer vaccine, which allows co-delivery of both TAA and 
immunostimulatory adjuvants 11, 12.  
In particular, biodegradable and biocompatible PLGA-based NPs containing 
cancer-associated antigen and TLR agonists are efficient at promoting DC maturation 
and activation, inducing antigen presentation by DCs via MHC I, eliciting the 
secretion of pro-inflammatory cytokines, and triggering potent CTL response against 
cancer 52, 53. In addition to PLGA-based NPs, bilayered liposomes, consisting of 
natural and/or synthetic lipids, are also recognized as attractive vaccine delivery 
systems, since the membrane fusion between liposomes and cells enables the efficient 
delivery of agents encapsulated within liposomes 69. Similar to PLGA-based NPs, 
numerous studies have also demonstrated the potential of liposomes, especially 
cationic liposomes, in co-delivering tumor-specific antigens and immunostimulatory 
adjuvants to induce the production of IgG 2a and IgG1antibodies, elicit robust cellular 
immune response, and promote the secretion of IFN-γ 64, 65.  
With these promising results, our aim focused on comparing the efficacy of 
PLGA NPs with liposomes as delivery platforms for vaccine adjuvant and studying 
the formulation effects on immune response to nanocarriers encapsulating TLR 7 
agonist. In the present study, we fabricated both cationic and anionic PLGA NPs as 
well as liposomes as four types of delivery vehicles, encapsulating the same 
immunostimulatory adjuvant, IMQ, to activate primary DCs and immortalized DCs. 
Both PLGA NPs and DMAB-PLGA NPs had an average diameter of ~250 nm, 
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whereas the average particle size of DSPC liposomes and DOTAP liposomes were 
~100 nm. Therefore, the diameters of all nanoformulations are within the size range 
preferential for DC internalization (<500 nm)，compared to PLGA macroparticles 
with an average size of ~1000nm 70. In addition, the loading amount of IMQ in PLGA 
NPs and DMAB-PLGA NPs was similar, ~20 μg/mg, close to the loading efficiency 
of PLGA macroparticles 70. Nevertheless, the IMQ content in two types of liposomes 
were both ~ 10𝜇g/mg. The differences in drug loading efficiency among four types of 
nanoformulations might be due to the fact that double-emulsion evaporation method 
could lead to greater loading efficiency of imidazoquinoline derivatives in PLGA NPs 
2. Furthermore, it was previously reported that using thin-film hydration and passive 
loading method to encapsulate imidazoquinolines, resiquimod, resulted in relatively 
low encapsulation efficiency (final weight loading of ∼1.1%) 71. As such, further 
studies are required to improve the loading efficiency of IMQ in liposomal 
formulations and achieve similar loading efficiency in all types of drug carriers for a 
comparable evaluation in vitro or in vivo.  
Cell viability assay was conducted to examine the cytotoxicity of four types of 
nanoformulations before in vitro DC activation and antigen presentation assay. As is 
indicated in our results, IMQ loaded PLGA NPs as well as their blank formulations 
had negligible cytotoxicity on both BMDCs and DC 2.4. However, IMQ loaded DSPC 
liposomes as well as their blank formulations showed cytotoxicity on BMDCs at 
concentrations greater than 10μM, which on the other hand, exerted negligible toxic 
effects on DC 2.4. IMQ loaded DMAB-PLGA NPs and their blank counterpart 
showed obvious cytotoxicity on BMDCs even when concentration was higher than 
1.25 μM, on DC 2.4 when concentration was greater than 2.5 μM. Additionally, both 
blank DOTAP liposomes and their loaded counterparts indicated cell-killing effect on 
BMDCs at concentrations greater than 1.25 μM, which, nevertheless, showed cell-
killing effect on DC 2.4 cells at concentrations higher than 10 μM.  
These results demonstrated better tolerance of immortalized DCs than primary 
DCs. Additionally, among four types of nanoformulations, PLGA NPs were the most 
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biocompatible nanocarriers with negligible cytotoxicity, which has been revealed in 
the previous study 2. In contrast, both DMAB-PLGA NPs and DOTAP liposomes 
exhibited obvious cytotoxic effects even at relatively low concentrations. One 
possible explanation was that cationic NPs were often cytotoxic due to their attractive 
interaction with negatively charged cell membranes and disruption of membrane 
integrity 72. Furthermore, two main components of these two nanoformulations, 
DMAB and DOTAP, had nonnegligible cytotoxicity, which have also been indicated 
in previous studies 73, 74. Improvements could be made through altering the ratio of 
DMAB or DOTAP in each cationic nanoformulation or synthesize lipid-biopolymer 
hybrid NPs in order to reduce the cytotoxicity 35. It is also reported that adsorption of 
cationic polymer carboxymethyl trimethyl chitosan (CM-TMC) to PLGA NPs could 
not only render the particle surface charge positive, but also show no significant 
cytotoxicity 75.  
In the above results, IMQ loaded PLGA NPs + OVA treatment induced the 
greatest costimulatory molecules (CD40, CD80, CD86) expression by BMDCs 
compared with other treatments, which further confirmed the superiority of PLGA 
NPs as vaccine adjuvants delivery platforms 2, 34. On the other hand, with respect to 
the DC 2.4 cells, OVA + free IMQ treatment were able to induce the highest expression 
of CD86 and CD40, albeit OVA + loaded PLGA NPs resulted in the greatest 
expression of CD80 among all the treatments. One potential explanation was that 
since the incubation time of treatments was 24h, IMQ encapsulated within the 
nanoformulations might not release completely. Thus, in vitro release study was 
required to evaluate the drug release profile of these nanocarriers. However, OVA + 
DMAB-PLGA NPs led to negligible expression of costimulatory molecules by DC 
2.4. We hypothesized that strong cytotoxicity of DMAB-PLGA NPs might impair the 
DCs’ capability of expressing costimulatory molecules.  
Regarding antigen presentation by BMDCs or DC 2.4 cells, our results indicated 
that of all nanocarriers, DOTAP liposomes could induce the highest expression of 
OVA257-264(SIINFEKL) peptide:MHC I complex, whereas the antigen expression 
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frequency in OVA+free IMQ treatment was greater than control and all the other 
formulation treatments. One possible explanation was that cationic DOTAP liposomes 
were more effective in promoting the antigen presentation by DCs via MHC I, which 
was critical in T cell activation and differentiation into functional CTLs. Also, Chen 
et al. reported that E7 peptide formulated with DOTAP could induce migration of 
activated DCs to the draining lymph node and generate robust antigen-specific CD8+ 
T lymphocyte responses 76. Furthermore, the superiority of OVA + free IMQ treatment 
to nanoformulation treatments in eliciting antigen presentation by DCs might also be 
partially due to the incomplete release of IMQ encapsulated within these nanocarriers.  
Also, we hypothesized that the strong cytotoxicity of DMAB-PLGA NPs might 
negatively affect the ability of DCs to process and present antigen peptide via MHC 
I. Definitely, more research is required to investigate the mechanism of formulation 
effects, particularly size and surface charge of nanoformulations, on immune response 




As one of the most promising strategies in cancer immunotherapy, cancer 
vaccines possess the unique ability to target host immune systems and co-deliver 
antigen and immunostimulatory adjuvants to induce antitumor immune response 11. 
The stimulation of T cell-mediated immunity through inducing the activation of DCs, 
the critical APCs, via TLR signaling have gained worldwide interests 25, 29-31. Here, 
we fabricated both cationic and anionic PLGA NPs as well as liposomes as vaccine 
adjuvant delivery vehicles to encapsulate the FDA-approved TLR 7 agonist, IMQ, 
and carry out preliminary in vitro DC activation and antigen presentation studies to 
evaluate the formulation effects on immune response to nanocarriers encapsulating 
TLR 7 agonist. We successfully developed four types of nanoformulations, PLGA 
NPs and DSPC liposomes, which were negatively charged, and DMAB-PLGA NPs 
and DOTAP liposomes, which were positively charged. The diameters of all 
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nanoformulations are within the size range preferential for DC internalization. In 
addition, both PLGA NPs and DSPC liposomes showed negligible cytotoxicity on 
DCs, whereas both DMAB-PLGA NPs and DOTAP liposomes exhibited obvious cell-
killing effects on DCs at low concentrations. Generally, anionic PLGA NPs were 
superior to other nanoformulations in eliciting the expression of costimulatory 
molecules by DCs, whereas cationic DOTAP liposomes were superior in inducing 
antigen presentation by DCs. Furthermore, DMAB-PLGA NPs resulted in negligible 
expression of costimulatory molecules by DC 2.4, which also caused almost no 
antigen expression by both BMDCs and DC 2.4. We expect these in vitro data can 
bring us one step further to understand the mechanism of formulation effects on 
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